Related Experiment Video
Updated: Aug 9, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
PU.1 drives psoriasis pathogenesis by promoting intermediate monocytes-to-M1 macrophage differentiation through
Liping Jin1, Shiyao Pei2, Liang Dong3
1Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China; Furong Laboratory, Changsha, Hunan, 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
The transcription factor PU.1 drives psoriasis inflammation by promoting intermediate monocyte differentiation. Inhibiting PU.1 with NHWD-870 shows promise for treating this skin condition.
Area of Science:
- Immunology
- Dermatology
- Molecular Biology
Background:
- Intermediate monocytes (IMs) expansion and differentiation are key in psoriasis pathogenesis.
- The precise molecular mechanisms regulating IMs in psoriasis remain unclear.
Purpose of the Study:
- To identify key regulators of intermediate monocyte (IM) expansion and differentiation in psoriasis.
- To investigate the therapeutic potential of targeting PU.1 in psoriasis models.
Main Methods:
- Single-cell RNA sequencing and flow cytometry on peripheral blood mononuclear cells from psoriasis patients.
- Myeloid-specific gene ablation in mouse models of psoriasiform dermatitis.
- Pharmacological inhibition of PU.1 using NHWD-870 in murine models.
Main Results:
- PU.1 (SPI1) was identified as a master regulator of IM expansion in psoriasis.
- PU.1 drives IM differentiation into pro-inflammatory M1 macrophages via Dectin-1 and SYK/NF-κB pathway activation.
- Pharmacological inhibition of PU.1 with NHWD-870 suppressed IM differentiation and ameliorated psoriasiform dermatitis in mice.
Conclusions:
- PU.1 is a critical therapeutic target for psoriasis.
- Targeting PU.1 with inhibitors like NHWD-870 offers a promising treatment strategy for psoriasis.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammation
Inflammatory Bowel Disease II: Ulcerative Colitis